XDR SHIGELLA US EMERGENCE — CDC MMWR APRIL 2026 Title: "Emergence of Extensively Drug-Resistant

via surveillance_reportRetrieved Apr 20, 2026View original source ↗

Grounds assessments

activeECDC will formally classify Candidozyma auris (formerly Candida auris) as endemic in ≥3 EU/EEA countries via a technical report, surveillance update, or risk assessment by 2026-10-17, formalizing the trajectory described in Medscape 2026-04-13 ("C auris Is Now Endemic in Europe. Can It Be Contained?") and CIDRAP 2025-09-11 ("Multidrug-resistant yeast cases rising rapidly in Europe, survey shows").60%activetetM-carrying N. gonorrhoeae prevalence in US surveillance reaches ≥30% by EOY 2026 OR ≥3 independent confirmed extensively drug-resistant (ceftriaxone+azithromycin+ciprofloxacin simultaneously resistant) N. gonorrhoeae transmission clusters documented in US/EU/AU during 2026, threatening the doxyPEP era and last-line cephalosporin therapy.60%activeCDC will publish a Morbidity and Mortality Weekly Report (MMWR) early release or health advisory specifically characterizing XDR Shigella (azithromycin + fluoroquinolone + 3GC resistant) geographic spread and treatment guidance within 60 days of the April 13 2026 emergence report (by June 12 2026), consistent with CDC's precedent of issuing MMWR early releases for novel drug-resistant Shigella phenotypes (2022-2023 ceftriaxone-resistant Shigella MMWR).60%expiredAt least one XDR Shigella case with genomic linkage to the US April 2026 emergence cluster will be confirmed in Australia, Canada, or Japan within 120 days (by August 13 2026), based on high-frequency MSM travel networks connecting these countries to the US, and the historical 2022-2023 pattern where drug-resistant Shigella reached high-income Pacific Rim countries within 8 months of initial US detection.40%expiredXDR Shigella (extensively drug-resistant, resistant to azithromycin + fluoroquinolones + 3GC) will establish sustained community transmission in at least 3 US states within 12 months of CDC's April 2026 emergence report, requiring updated CDC treatment guidance and triggering enhanced surveillance protocols.40%activeXDR Shigella (resistant to azithromycin + fluoroquinolones + 3GC simultaneously) proportion in PulseNet US surveillance will exceed 10% of submitted isolates by end of 2026, up from 8.5% in 2023 (MMWR mm7513a1 data endpoint). CIDRAP Jan 14 2026 reported "novel XDR Shigella strain identified in Los Angeles" — the only confirmed 2026 XDR Shigella signal. MMWR 2011-2023 trend shows acceleration: 0% pre-2016 → 8.5% by 2023, with 84% of XDR cases in 2022-2023.50%resolvedA phylogenetically linked XDR Shigella case will be documented outside the United States by October 2026, tracing to the Los Angeles novel XDR strain identified December 2024/January 2026 via the MSM sexual transmission network50%activeAt least one additional case of XDR Shigella sonnei carrying BOTH blaDHA-1 (cephalosporinase) and blaCTX-M-15 (ESBL) — the dual-cephalosporinase phenotype first reported in two epidemiologically unlinked LA patients (Yang et al., Antimicrobial Stewardship & Healthcare Epidemiology, CIDRAP 2026-01-14) — will be reported in any T1 source (CDC, MMWR, peer-reviewed journal, ECDC, GLASS) by 2026-07-21.60%expiredWHO will issue a global health advisory or Disease Outbreak News specifically addressing the XDR Shigella phenotype (azithromycin + fluoroquinolone + 3GC resistant) within 90 days of the US April 2026 emergence cluster, recognizing international spread risk.50%expiredFDA will initiate a formal regulatory pathway (emergency use, compassionate use IND, or expedited NDA) for pivmecillinam in the US within 180 days of the April 2026 XDR Shigella emergence, given that XDR phenotype (azithromycin + FQ + 3GC resistant) leaves only carbapenems and pivmecillinam as clinically viable options, and pivmecillinam is currently approved in Europe and Canada but not FDA-approved.50%expiredXDR Shigella (azithromycin + fluoroquinolone + 3GC resistant) will be confirmed in at least one US state beyond the index cluster state within 90 days of the April 13 2026 CDC emergence report, based on the very low inoculum transmission threshold (~10-100 organisms) and MSM sexual network connectivity between major US metro areas.60%expiredAt least one XDR Shigella case phylogenetically linked to the US April 2026 cluster will be confirmed in a UK, French, or Dutch sexual health clinic or MSM outbreak investigation by September 2026, consistent with the 2022-2023 ceftriaxone-resistant Shigella international spread pattern through MSM travel and sexual networks.50%expiredCDC will issue updated XDR Shigella clinical guidance or treatment advisory by December 31, 2026, specifying carbapenem-class or pivmecillinam as first-line therapy for confirmed XDR Shigella cases, triggered by the April 2026 XDR emergence and the complete failure of standard empirical enteric treatment regimens.60%

Evidence content

XDR SHIGELLA US EMERGENCE — CDC MMWR APRIL 2026

Title: "Emergence of Extensively Drug-Resistant — research event update (updated 2026-04-20T07:12)

XDR SHIGELLA US EMERGENCE — CDC MMWR APRIL 2026

Title: "Emergence of Extensively Drug-Resistant

Field	Value
connector_id	surveillance_report
content_hash	e990e4313de70776f467eb403349048cecaa20b61ca8eb72fe2af460867599b7
date	2026-04-20
document_id	document:surveillance_report:192811a92214dd9c4183e754
event_type	surveillance_report
evidence_envelope	{"source":{},"document_id":"document:surveillance_report:192811a92214dd9c4183e754"}
extracted_at	2026-04-20T07:12:31.610546+00:00
headline	XDR SHIGELLA US EMERGENCE — CDC MMWR APRIL 2026

Title: "Emergence of Extensively Drug-Resistant | | payload | None | | payload_kind | surveillance_report | | research_domain | generic | | retrieved_at | 2026-04-20T07:12:31.610534+00:00 | | run_id | | | schema_version | 1 | | scope | amr | | source_meta | {"document_id":"document:surveillance_report:192811a92214dd9c4183e754"} | | source_url | https://www.cdc.gov/mmwr/volumes/75/wr/mm7515a1.htm | | summary | XDR SHIGELLA US EMERGENCE — CDC MMWR APRIL 2026

Title: "Emergence of Extensively Drug-Resistant Shigellosis in the United States — 2026" Source: CDC MMWR, April 2026 (volume/page approximate; confirmed via CIDRAP Apr 17 2026 coverage) Signal Tier: T1 (CDC MMWR — highest domestic surveillance authority)

DEFINITION — XDR SHIGELLA: Shigella strains simultaneously resistant to:

Azithromycin (first-line for adults)
Fluoroquinolones (ciprofloxacin — second-line)
Third-generation cephalosporins (ceftriaxone — pediatric first-line) This leaves no reliable oral outpatient options for most populations.

KEY FINDINGS (Apr 2026 MMWR):

XDR Shigella cases confirmed across multiple US states; outbreak investigation ongoing
Resistance profile expands on the 2023 CDC Health Advisory (which fl | | tier | |

Technical metadataPipeline attribution for verification

Connector: surveillance_report
Payload kind: surveillance_report
Run ID: —
Schema version: —

Assessment unavailable

This assessment could not be loaded right now because no recent cached snapshot is available.

XDR SHIGELLA US EMERGENCE — CDC MMWR APRIL 2026

Title: "Emergence of Extensively Drug-Resistant — research event update (updated 2026-04-20T07:12)

XDR SHIGELLA US EMERGENCE — CDC MMWR APRIL 2026

Title: "Emergence of Extensively Drug-Resistant

Field	Value
connector_id	surveillance_report
content_hash	e990e4313de70776f467eb403349048cecaa20b61ca8eb72fe2af460867599b7
date	2026-04-20
document_id	document:surveillance_report:192811a92214dd9c4183e754
event_type	surveillance_report
evidence_envelope	{"source":{},"document_id":"document:surveillance_report:192811a92214dd9c4183e754"}
extracted_at	2026-04-20T07:12:31.610546+00:00
headline	XDR SHIGELLA US EMERGENCE — CDC MMWR APRIL 2026

DEFINITION — XDR SHIGELLA: Shigella strains simultaneously resistant to:

Azithromycin (first-line for adults)
Fluoroquinolones (ciprofloxacin — second-line)
Third-generation cephalosporins (ceftriaxone — pediatric first-line) This leaves no reliable oral outpatient options for most populations.

KEY FINDINGS (Apr 2026 MMWR):

XDR Shigella cases confirmed across multiple US states; outbreak investigation ongoing
Resistance profile expands on the 2023 CDC Health Advisory (which fl | | tier | |